Abstract
Since CCH was approved by regulatory authorities, further data have emerged. CCH is, in the short term, effective in reducing cord contracture. Higher doses reduce the need for multiple injections on separate occasions but at the expense of increased skin splitting. Local anaesthetic prior to manipulation improves correction but increases the risk of skin splitting. Delayed manipulation allows more convenient scheduling. The relatively high risk of recurrence must be factored into a treatment algorithm. Patient satisfaction is high but may decline with time as the disease recurs. Side effects are common and occasionally alarming, but most are mild and resolve promptly. Clinically significant complications (allergic shock, tendon rupture) are rare. Further comparative information is required for efficacy, cost-effectiveness, satisfaction and recurrence. Because CCH is not suitable for all cords, randomised trials will be of limited value, and registry data are likely to be informative.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Gilpin D, Coleman S, Hall S, Houston A, Karrasch J, Jones N. Injectable collagenase Clostridium histolyticum: a new nonsurgical treatment for Dupuytren’s disease. J Hand Surg [Am]. 2010;35:2027–38.
Hurst LC, Badalamente MA, Hentz VR, Hotchkiss RN, Kaplan FT, Meals RA, Smith TM, Rodzvilla J. Injectable collagenase clostridium histolyticum for Dupuytren’s contracture. N Engl J Med. 2009;361:968–79.
Witthaut J, Jones G, Skrepnik N, Kushner H, Houston A, Lindau TR. Efficacy and safety of collagenase Clostridium histolyticum injection for Dupuytren contracture: short-term results from 2 open-label studies. J Hand Surg [Am]. 2013;38:2–11.
Warwick D, Arner M, Pajardi G, Reichert B, Szabo Z, Masmejean EH, Fores J, Chapman DS, Gerber RA, Huard F, Seghouani A, Szczypa PP. Collagenase Clostridium histolyticum in patients with Dupuytren’s contracture: results from POINT X, an open-label study of clinical and patient-reported outcomes. J Hand Surg Eur. 2015;40E:124–32.
Warwick D, Graham D, Worley P. New insights into the immediate outcome of collagenase injections for Dupuytren’s contracture. J Hand Surg Eur. 2016;41:583–8.
Bainbridge C, Gerber RA, Szczypa PP, Smith T, Kushner H, Cohen B, Hellio Le Graverand-Gastineau MP. Efficacy of collagenase in patients who did and did not have previous hand surgery for Dupuytren’s contracture. J Plast Surg Hand Surg. 2012;46:177–83.
Denkler K. Collagenase for recurrent dupuytren contracture with skin grafts. J Hand Surg [Am]. 2013;38:1264.
Dreise MM, Stenekes MW, Werker PM. Collagenase treatment for Dupuytren disease of the thumb and first web. J Hand Surg [Am]. 2016;41:348–53.
Gaston RG, Larsen SE, Pess GM, Coleman S, Dean B, Cohen BM, Kaufman G, Tursi JP, Hurst LC. The efficacy and safety of concurrent collagenase clostridium histolyticum injections for 2 Dupuytren contractures in the same hand. J Hand Surg [Am]. 2015;40:1963–71.
Kaplan TD, Badalamente M, Hurst L, et al. Delayed manipulation following Clostridial Collagenase histolyticum injection for Dupuytren contracture. J Hand Surg. 2013;38:52–3.
Mickelson DT, Noland SS, Watt AJ, et al. Prospective RCT comparing 1-versus 7-day manipulation following collagenase injection for Dupuytren contracture. J Hand Surg. 2014;39:1933–41.
Scherman P, Jenmalm P, Dahlin LB. One-year results of needle fasciotomy and collagenase injection in treatment of Dupuytren’s contracture: a two-centre prospective randomized clinical trial. J Hand Surg Eur. 2016;41:577–82.
Stromberg J, Ibsen-Sorensen A, Friden J. Comparison of treatment outcome after collagenase and needle fasciotomy for Dupuytren contracture: a randomised, single blinded, clinical trial with a 1 year follow up. J Hand Surg [Am]. 2016;41:873–80.
Zhou C, Hovius SE, Slijper HP, Feitz R, Van Nieuwenhoven CA, Pieters AJ, Selles RW. Collagenase Clostridium histolyticum versus limited fasciectomy for Dupuytren’s contracture: outcomes from a multicenter propensity score matched study. Plast Reconstr Surg. 2015;136:87–97.
Zhou C, Hovius S, Zuidam MJ, Smit X, Feitz R, Selles RW. Patient satisfaction with hand function after fasciectomy for Dupuytren’s contracture. Plast Reconstr Surg. 2016;138:649–55.
Kan HJ, de Bekker-Grob EW, van Marion ES, van Oijen GW, van Nieuwenhoven CA, Zhou C, Hovius SE, Selles RW. Patients’ preferences for treatment for Dupuytren’s disease: a discrete choice experiment. Plast Reconstr Surg. 2016;137:165–73.
Bradley J, Warwick D. Patient satisfaction with collagenase. J Hand Surg. 2016;41(A):689–97.
Kan HJ, Verrijp FW, Huisstede BM, Hovius SE, van Nieuwenhoven CA, Selles RW. The consequences of different definitions for recurrence of Dupuytren’s disease. J Plast Reconstr Aesthet Surg. 2013;66:95–103.
Felici N, Marcoccio I, Giunta R, Haerle M, Leclercq C, Pajardi G, Wilbrand S, Georgescu AV, Pess G. Dupuytren contracture recurrence project: reaching consensus on a definition of recurrence. Handchir Mikrochir Plast Chir. 2014;46:350–4.
Peimer CA, Wilbrand S, Gerber RA, Chapman D, Szczypa PP. Safety and tolerability of collagenase clostridium hystiolyticum and fasciectomy for Dupuytrens contracture. J Hand Surg Eur. 2014;40:141–9.
Eberlin KR, Kobraei EM, Nyame TT, Bloom JM, Upton J. Salvage palmar fasciectomy after initial treatment with collagenase clostridium hystiolyticum. Plast Reconstr Surg. 2015;135:1000–6.
Hay DC, Louie DL, Earp BE, Kaplan FT, Akelman E, Blazar PE, et al. Surgical findings in the treatment of Dupuytren’s disease after initial treatment with clostridial collagenase. J Hand Surg Eur. 2014;39:463–5.
Peimer C, Blazar P, Coleman S, Kaplan T, Smith T, Lindau T. Dupuytren contracture recurrence following treatment with collagenase Clostridium histolyticum (CORDLESS [collagenase option for reduction of Dupuytren long-term evaluation of safety study]): 5-year data. J Hand Surg. 2015;40:1597–605.
Watt AJ, Curtin CM, Hentz VR. Collagenase injection as nonsurgical treatment of Dupuytren’s disease: 8-year follow-up. J Hand Surg [Am]. 2010;35:534–9.
Atroshi I, Jesper Nordenskjöld J, Lauritzson A, Ahlgren E, Waldau J, Waldén M. Collagenase treatment of Dupuytren’s contracture using a modified injection A prospective cohort study of skin tears in 164 hands, including short-term outcome method. Acta Orthop. 2015;86:310–5.
Verheyden JR. Early outcomes of a sequential series of 144 patients with Dupuytren’s contracture treated by collagenase injection using an increased dose, multi-cord technique. J Hand Surg Eur. 2015;40:133–40.
Peimer CA, McGoldrick CA, Greg Kaufman G. Nonsurgical treatment of Dupuytren contracture: 3-year safety results using collagenase Clostridium histolyticum. J Hand Surg [Am]. 2013;38:e52.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Warwick, D. (2018). Follow-up Studies, Satisfaction, Recurrence, Dosage and Drug Safety. In: Pajardi, G., Badalamente, M., Hurst, L. (eds) Collagenase in Dupuytren Disease . Springer, Cham. https://doi.org/10.1007/978-3-319-65822-3_8
Download citation
DOI: https://doi.org/10.1007/978-3-319-65822-3_8
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-65821-6
Online ISBN: 978-3-319-65822-3
eBook Packages: MedicineMedicine (R0)